Kahira Pharmaceuticals & Chemical Industries Company (EGX:CPCI)
Egypt · Delayed Price · Currency is EGP 590.26
-2.25 (-0.38%)
At close: Oct 22, 2026
EGX:CPCI Ratios and Metrics
Market cap in millions EGP. Fiscal year is July - June.
Millions EGP. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 21, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 8,815 | 2,676 | 997 | 637 | 551 | 539 | |
Market Cap Growth | 109.34% | 168.26% | 56.67% | 15.47% | 2.38% | 25.17% |
Enterprise Value | 8,910 | 2,740 | 1,128 | 710 | 475 | 432 |
Last Close Price | 590.26 | 168.55 | 55.89 | 33.04 | 25.22 | 22.22 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 21, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
PE Ratio | 17.47 | 6.03 | 4.05 | 6.56 | 3.33 | 4.33 |
Forward PE | - | 6.22 | 6.22 | 6.22 | 6.22 | 6.22 |
PS Ratio | 3.68 | 1.29 | 0.73 | 0.63 | 0.50 | 0.51 |
PB Ratio | 7.59 | 2.56 | 1.20 | 0.94 | 0.69 | 0.77 |
P/TBV Ratio | 7.59 | 2.56 | 1.20 | 0.94 | 0.70 | 0.77 |
P/FCF Ratio | 57.35 | 11.18 | 21.38 | 67.35 | 15.98 | 3.89 |
P/OCF Ratio | 41.42 | 7.07 | 3.79 | 7.19 | 10.64 | 3.32 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 21, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
EV/Sales Ratio | 3.72 | 1.32 | 0.83 | 0.71 | 0.43 | 0.41 |
EV/EBITDA Ratio | 13.12 | 4.57 | 3.88 | 8.04 | 2.29 | 2.76 |
EV/EBIT Ratio | 14.21 | 4.83 | 3.95 | 9.26 | 2.47 | 2.76 |
EV/FCF Ratio | 57.97 | 11.45 | 24.19 | 75.14 | 13.76 | 3.12 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 21, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Debt / Equity Ratio | 0.14 | 0.21 | 0.28 | 0.24 | 0.07 | - |
Debt / EBITDA Ratio | 0.25 | 0.37 | 0.82 | 1.77 | 0.28 | - |
Debt / FCF Ratio | 1.10 | 0.93 | 5.09 | 17.38 | 1.69 | - |
Net Debt / Equity Ratio | 0.08 | 0.05 | 0.08 | 0.04 | -0.07 | -0.21 |
Net Debt / EBITDA Ratio | 0.14 | 0.08 | 0.24 | 0.28 | -0.26 | -0.94 |
Net Debt / FCF Ratio | 0.62 | 0.21 | 1.48 | 2.63 | -1.55 | -1.06 |
Asset Turnover | 1.15 | 1.17 | 0.99 | 0.84 | 0.99 | 1.03 |
Inventory Turnover | 2.72 | 2.44 | 1.94 | 2.09 | 2.56 | 2.59 |
Quick Ratio | 1.07 | 0.98 | 1.17 | 1.05 | 1.90 | 1.77 |
Current Ratio | 1.77 | 1.83 | 2.25 | 2.21 | 3.08 | 2.56 |
Return on Equity (ROE) | 47.65% | 47.23% | 32.54% | 13.17% | 22.13% | 18.31% |
Return on Assets (ROA) | 18.83% | 20.04% | 12.96% | 3.98% | 10.73% | 9.50% |
Return on Invested Capital (ROIC) | 40.89% | 43.88% | 27.75% | 8.08% | 22.92% | 21.11% |
Return on Capital Employed (ROCE) | 46.80% | 46.20% | 27.30% | 9.70% | 22.40% | 22.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 21, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Earnings Yield | 5.72% | 16.58% | 24.67% | 15.25% | 30.06% | 23.08% |
FCF Yield | 1.74% | 8.94% | 4.68% | 1.49% | 6.26% | 25.73% |
Dividend Yield | 2.84% | 9.34% | 19.21% | 11.73% | 13.54% | 11.09% |
Payout Ratio | 42.07% | 49.76% | 34.75% | 103.84% | 45.37% | 62.53% |
Total Shareholder Return | 2.84% | 9.34% | 19.21% | 11.73% | 13.54% | 11.09% |